Phosphorylation of BCL2 at the Ser70 site mediates RANKL-induced osteoclast precursor autophagy and osteoclastogenesis
Authors:
Open Access
- 19 February 2022
- journal article
- research article
- Published by Springer Nature in Molecular Medicine
- Vol. 28 (1) , 1-16
Abstract
Background: Phosphorylation modification of BCL2 is involved in receptor activator of nuclear factor-κB ligand (RANKL)-induced autophagy of osteoclast precursors (OCPs) and osteoclastogenesis. As an antiapoptotic molecule, the role of BCL2 phosphorylation in osteoclastogenesis is unknown. This study aimed to explore how BCL2 phosphorylation at specific sites regulates osteoclastogenesis. Methods: We first examined the effects of RANKL on BCL2 phosphorylation at different sites (Ser70 and Ser87) in OCPs. In vivo, transgenic mice overexpressing RANKL (Tg-hRANKL mice) were used to observe the effects of RANKL on phosphorylated BCL2 at different sites in OCPs of trabecular bone. Subsequently, using site-directed mutagenesis, we observed the respective effect of BCL2 mutations at different phosphorylation sites in OCPs on osteoclastogenesis, apoptosis, autophagy and the affinity between BCL2 and Beclin1/BAX under RANKL intervention. Results: RANKL promoted BCL2 phosphorylation at the Ser70 (S70) site, but not the Ser87 (S87) site, in OCPs. Moreover, Tg-hRANKL mice had stronger BCL2 phosphorylation capacity at S70, not S87, in the OCPs of trabecular bone than wild-type mice in the same nest. Furthermore, BCL2 mutation at S70, not S87, inhibited RANKL-induced osteoclast differentiation and bone resorption activity. In addition, BCL2 mutation at S70 promoted OCP apoptosis, while BCL2 mutation at S87 showed the opposite effect. Remarkably, the BCL2 mutation at S70, not S87, inhibited OCP autophagic activity. Furthermore, BCL2 mutation at S70 enhanced the coimmunoprecipitation of BCL2 and Beclin1, whereas BCL2 mutation at S87 enhanced the coimmunoprecipitation of BCL2 and BAX in OCPs. More importantly, OCP autophagy, osteoclast differentiation and resorption pits inhibited by BCL2 mutation at S70 could be reversed by Beclin1 upregulation with TAT-Beclin1. Conclusion: RANKL activates OCP autophagy through BCL2 phosphorylation at S70, thereby promoting osteoclastogenesis, which indicates that the inactivation of BCL2 at S70 in OCPs may be a therapeutic strategy for pathological bone loss.Keywords
Funding Information
- Fujian Provincial Hospital Firestone Fund (2019HSJJ24)
- Natural Science Foundation of Fujian Province (2020J011079)
- The Sailing Fund from Fujian Medical University (2018QH1134)
- The Postdoctoral Science Foundation of China (2020M672731)
This publication has 50 references indexed in Scilit:
- Autophagy Proteins Regulate the Secretory Component of Osteoclastic Bone ResorptionDevelopmental Cell, 2011
- CXC Chemokine Ligand 2 Induced by Receptor Activator of NF-κB Ligand Enhances OsteoclastogenesisThe Journal of Immunology, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Repression of PKR mediates palmitate-induced apoptosis in HepG2 cells through regulation of Bcl-2Cell Research, 2009
- Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxiaNature, 2008
- JNK1-Mediated Phosphorylation of Bcl-2 Regulates Starvation-Induced AutophagyMolecular Cell, 2008
- Role of Bcl2 in Osteoclastogenesis and PTH Anabolic Actions in BoneJournal of Bone and Mineral Research, 2008
- Bcl-2 Antiapoptotic Proteins Inhibit Beclin 1-Dependent AutophagyCell, 2005
- Osteoclast differentiation and activationNature, 2003
- Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and DeathScience, 2001